Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Creative Tech Contraptions That Will Work on Your Life- The Most Vital Crossroads in Olympic History
- Fundamental Venture The board Apparatuses for Remote Groups
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- 5 VIP Voice Exhibitions in Energized Movies
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
